Country: Նոր Զելանդիա
language: անգլերեն
source: Medsafe (Medicines Safety Authority)
Furosemide 10 mg/mL; Furosemide 10 mg/mL
Hospira NZ Ltd
Furosemide 10 mg/mL
20 mg/2mL
Solution for injection
Active: Furosemide 10 mg/mL Excipient: Sodium chloride Sodium hydroxide Water for injection Active: Furosemide 10 mg/mL Excipient: Sodium chloride Sodium hydroxide Water for injection
Ampoule, glass, 50 x 2ml amp, 50 dose units
Prescription
Prescription
Arandy Laboratories Ltd
DBL™ Frusemide Injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. DBL™ Frusemide Injection is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.
Package - Contents - Shelf Life: Ampoule, glass, 50 x 2ml amp - 50 dose units - 36 months from date of manufacture stored at or below 25°C
1986-03-04
Data Sheet – New Zealand Hosp 3.0 1 DBL™ FRUSEMIDE INJECTION NAME OF MEDICINE Frusemide PRESENTATION DBL™ Frusemide Injection is available as a 20 mg/2 mL injection, prepared with sodium hydroxide giving solutions having a pH of about 9. USES _ACTIONS _ Frusemide is a potent diuretic. It inhibits sodium and chloride absorption in the ascending limb of Henle's loop and in both the proximal and distal tubules. The high degree of efficacy is due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase or aldosterone. Frusemide may produce a prompt diuresis in cases which have previously proved resistant to other diuretics. Frusemide has no significant pharmacological actions other than on renal function. _PHARMACOKINETICS, _ _ABSORPTION _ Frusemide is rapidly absorbed from the gastrointestinal tract. Absorption rates in healthy subjects have been reported from 60-69% and from 43-46% in patients with end stage renal failure. The onset of diuresis following intravenous administration is within 5 minutes and somewhat later after intramuscular administration. The peak effect occurs within the first half hour. The duration of diuretic effect is approximately 2 hours. _DISTRIBUTION _ Frusemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 µg/ml are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations. _METABOLISM _ Recent evidence suggests that frusemide glucuronide is the only, or at least the major, bio-transformation product of frusemide in man. _EXCRETION _ In patients with normal renal f read_full_document